Andrew D Cherniack

Group Leader

Dana-Farber Cancer Institute
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (73)

Exon 20 insertions of HER2, encoded by erb-b2 receptor tyrosine kinase 2 ( ERBB2 ), and other activating HER2 mutations occur in 2% to 4% of lung adenocarcinomas, but there are only limited therapeutic options available for these patients. Sevabertinib (BAY 2927088) is a potent and reversible dual EGFR–HER2 inhibitor that is selective with respect to wild-type EGFR. In this study, we report the preclinical activity of sevabertinib in lung cancer models harboring alterations of HER2, including exon 20 insertions, point mutations, and amplification of wild-type ERBB2 . We furthermore demonstrate the activity of sevabertinib in a cancer cell line dependent on a fusion of neuregulin-1, a ligand for the HER2 family member and heterodimerization partner, HER3. Finally, we report patient responses to sevabertinib from a phase 1/2 clinical trial, indicating potential benefit for patients with HER2-mutant lung cancer. Significance: Additional therapeutic options are needed for patients with lung cancer with HER2 activating mutations, including exon 20 insertions. Sevabertinib shows activity against ERBB2 -encoded HER2 exon 20 insertions in preclinical models of lung cancer, corroborated by early data from a phase 1/2 clinical trial.

Year:

2026

Ovarian cancers and microsatellite stable (MSS) colorectal cancers are insensitive to anti–programmed cell death 1 (PD-1) immunotherapy, and new immunotherapeutic approaches are needed. Preclinical data suggest a relationship between immunotherapy resistance and elevated angiopoietin 2 levels. We performed a phase I dose escalation study of pembrolizumab and the angiopoietin 1/2 inhibitor trebananib (NCT03239145). This multicenter trial enrolled patients with metastatic ovarian cancer or MSS colorectal cancer. Trebananib was administered intravenously weekly for 12 weeks with 200 mg intravenous pembrolizumab every 3 weeks. The toxicity profile of this combination was manageable, and the protocol-defined highest dose level (trebananib 30 mg/kg weekly plus pembrolizumab 200 mg every 3 weeks) was declared the maximum tolerated dose. The objective response rate for all patients was 7.3% (90% confidence interval, 2.5%–15.9%). Three patients with MSS colorectal cancer had durable responses for ≥3 years. One responding patient’s colorectal cancer harbored a POLE mutation. The other two responding patients had left-sided colorectal cancers, with no baseline liver metastases, and genomic analysis revealed that they both had KRAS wild-type, ERBB2-amplified tumors. After development of acquired resistance, biopsy of one patient’s KRAS wild-type ERBB2-amplified tumor showed a substantial decline in tumor-associated T cells and an increase in immunosuppressive intratumoral macrophages. Future studies are needed to carefully assess whether clinicogenomic features, such as lack of liver metastases, ERBB2 amplification, and left-sided tumors, can predict increased sensitivity to PD-1 immunotherapy combinations.

Year:

2025

Supplementary Figure 21. (A) Intratumoral, (B) tumor-stroma interface, and (C) total CD8+ PD1+ T cells in ATMMUT and ATMWT NSCLCs. (D) Intratumoral, (E) tumor-stroma interface, and (F) total FOXP3+ immune cells in ATMMUT and ATMWT NSCLCs.

Year:

2025

Supplementary Figure 14. (A) Objective response rate, (B) progression-free survival, and (C) overall survival to PD-(L)1 immune checkpoint blockade monotherapy among patients with advanced/metastatic PD-L1 negative (

Year:

2025

Supplementary Figure 7. (A) Histograms showing the distribution of deleterious class I and class II ATM mutations with lost or intact ATM protein expression by IHC. (B) Histograms showing the distribution of deleterious missense, nonsense, splice site, and insertion/deletion mutations with lost or intact ATM protein expression by IHC. (C) proportion of NSCLCs with predicted benign and predicted pathogenic ATM missense mutations with lost and intact ATM expression by IHC.

Year:

2025

Supplementary Figure 29. Box plot showing immune cell subsets significantly enriched among ATMMUT versus ATMWT NSCLC as assessed by deconvoluting bulky RNAseq data from the TCGA-NSCLC dataset. Non-significant results are not shown.

Year:

2025

Supplementary Figure 19. (A) Objective response rate, (B) progression-free survival, and (C) overall survival to PD-(L)1 immune checkpoint blockade monotherapy among patients with ATMMUT NSCLC, according to KEAP1 mutation. (D) Objective response rate, (E) progression-free survival, and (F) overall survival to PD-(L)1 immune checkpoint blockade in combination with platinum doublet chemotherapy among patients with ATMMUT NSCLC, according to KEAP1 mutation status

Year:

2025

Supplementary Figure 10. (A) Progression-free and (B) overall survival among all patients with stage III NSCLC according to ATM mutation status. (C) Progression-free and (D) overall survival among patients with stage III NSCLC who received concurrent chemoradiotherapy followed by durvalumab maintenance according to ATM mutation status.

Year:

2025

Supplementary Figure 5. (A) Median distance of each missense mutation from the closest intron start. (B) Median distance of each missense mutation from the closest intron end. (C) Proportion of cases with ATM loss and ATM intact expression by IHC in NSCLC samples with ATM mutation and ATM loss-of-heterozygosity (LOH).

Year:

2025

Supplementary Figure 17. (A) Objective response rate, (B) progression-free survival, and (C) overall survival to PD-(L)1 inhibition among patients with advanced/metastatic NSCLC, according to ATM expression by immunohistochemistry.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (36)

Alessandro Di Federico

University of Bologna

ITALY
View details

Mark Awad

Chief, Thoracic Oncology Service

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Hersh Gupta

Dana-Farber Cancer Institute

UNITED STATES
View details

Annacarolina da Silva

Assistant Professor of Pathology and Laboratory Medicine

Weill Cornell Medical College

UNITED STATES
View details

Livio Trusolino

Full Professor, University of Torino School of Medicine

Candiolo Cancer Institute, FPO-IRCCS

ITALY
View details

Paolo Grassi

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

Shahab Sarmashghi

Broad Institute

UNITED STATES
View details

Emma Welsh

Dana-Farber Cancer Institute

UNITED STATES
View details

Kimmie Ng

Associate Professor of Medicine, Harvard Medical School

Dana-Farber Cancer Institute

UNITED STATES
View details

Mizuki Nishino

King’s College London

UNITED STATES
View details

Ryan Corces

Assistant Investigator

Gladstone Institutes

UNITED STATES
View details

Federica Piccioni

Group Leader

Broad Institute

UNITED STATES
View details

Nancy Lin

Associate Professor of Medicine

Dana-Farber Cancer Institute

UNITED STATES
View details

Richard Schilsky

Chief Medical Officer

-

UNITED STATES
View details

Howard Y. Chang

Stanford University School of Medicine

UNITED STATES
View details

Jeffrey Clark

Associate Professor

Harvard University

UNITED STATES
View details

Daniel Gomez

Chair, Radiation Oncology

Laura and Isaac Perlmutter Cancer Center at NYU Langone Health

UNITED STATES
View details

Srivatsan Raghavan

Assistant Professor

Dana-Farber Cancer Institute

UNITED STATES
View details

Bruno Bockorny

Beth Israel Deaconess Medical Center

UNITED STATES
View details

Christina Curtis

Professor of Medicine & Genetics

Stanford University

UNITED STATES
View details

Scott Rodig

Professor of Pathology

Beth Israel Deaconess Medical Center

UNITED STATES
View details

Andrea Bertotti

Candiolo Cancer Institute

ITALY
View details

Neal Lindeman

Vice Chair, Molecular Pathology and Laboratory Medicine

Weill Cornell Medicine

UNITED STATES
View details

Andrew McPherson

Assistant Attending

Sloan Kettering Institute

UNITED STATES
View details

Brittany Bychkovsky

Assistant Professor of Medicine

Dana-Farber Cancer Institute

UNITED STATES
View details

Elizabeth Cohen

Dana-Farber Cancer Institute

UNITED STATES
View details

Keith Ligon

Chief of Neuropathology/Principal Investigator

Dana-Farber Cancer Institute

UNITED STATES
View details

Steven Corsello

Stanford University

UNITED STATES
View details

Sheheryar Kabraji

Associate Professor

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Chen Yuan

Assistant Professor

Cedars-Sinai Medical Center

UNITED STATES
View details

Michael Rosenthal

Brigham and Women's Hospital

UNITED STATES
View details

Filipa Lynce

Dana-Farber Cancer Institute

UNITED STATES
View details

William Greenleaf

Professor

Stanford University

UNITED STATES
View details

Eric Winer

Director

Yale University

UNITED STATES
View details

PETER W LAIRD

Professor, Peter and Emajean Cook Endowed Chair in Epigenetics

Van Andel Institute

UNITED STATES
View details

Matthew Meyerson

Director, Center for Cancer Genomics

Dana-Farber Cancer Institute

UNITED STATES
View details